Our group showed that the presence of mutations in SETBP1, RUNX1, or EZH2 genes is associated with a worse response to HMA and inferior OS in a cohort of patients with MDS/MPN treated with AZA or DAC [24]. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.